We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Siemens Healthineers - Laboratory Diagnostics

Provides advanced laboratory diagnostics solutions for the medical industry read more Featured Products: More products

Download Mobile App




Siemens Introduces New Intelligent, Integrated IVD Solutions Virtually at EUROMEDLAB 2021

By LabMedica International staff writers
Posted on 29 Nov 2021
Print article
Image: Atellica Solution (Photo courtesy of Siemens Healthineers)
Image: Atellica Solution (Photo courtesy of Siemens Healthineers)

Siemens Healthineers (Erlangen, Germany) introduced new intelligent, integrated IVD solutions virtually at the XXIV IFCCEFLM European Congress of Clinical Chemistry and Laboratory Medicine (EuroMedLab Congress 2021).

EuroMedLab Congress 2021 was to be held as an in-presence meeting between 28th of November and 2nd of December in Germany but was postponed after the country was hit very hard by a fourth wave of COVID-19. However, those interested participated virtually in the Siemens EUROMEDLAB Experience that showcased its latest innovations. Siemens offered a virtual booth tour, held product demonstrations, and hosted expert presentations and on-demand webinars.

At its virtual booth, Siemens demonstrated its Atellica Solution comprising flexible, scalable, automation-ready immunoassay and chemistry analyzers with integrated automation. The company also highlighted of its extensive Atellica portfolio of tests that deliver accurate, clinically relevant results, including SARS-CoV-2 antibody tests, COVID-19 antigen assay, Atellica IM B·R·A·H·M·S PCT Assay for early sepsis risk assessment, and proven, true high-sensitivity cardiac troponin I assays for managing chest pain patients. Siemens highlighted the Atellica CI 1900 System which is being developed for the lower-to-mid-volume laboratories. It is planned to utilize the same menu, reagents, consumables, and detection technology as the Atellica Solution. Siemens also demonstrated how its Atellica Diagnostics IT can help labs unify data and optimize workflow with simple, open, and scalable solutions.

Siemens held virtual product demonstrations of its new Atellica Hematology Portfolio which pairs automation, intelligence, and extended parameters to streamline operations and support accurate clinical decision-making. The company presented the Sysmex CN-3000 and CN-6000 fully automated, mid-and high-volume coagulation analyzers which combine size, speed, intelligence, and flexibility.

In addition, Siemens virtually demonstrated its epoc blood analysis system, a handheld, wireless solution to enable comprehensive blood analysis testing at the patient’s side on a single room temperature test card, with results in less than a minute. Visitors to its virtual booth also saw the DCA Vantage Analyzer that helps monitor glycemic control and detect early kidney disease in environments ranging from the physician’s office to remote, point-of-care coordinated sites in hospitals and multisite practices. Among other products, Siemens virtually demonstrated rapid clinical decision-making with lab-comparable results from its broad POC blood gas portfolio, its high-sensitivity troponin I testing solution, and the new Sysmex CN-3000 and CN-6000 Systems for accelerating hemostasis workflows.

Related Links:
Siemens Healthineers 

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
TRAcP 5b Assay
TRAcP 5b (BoneTRAP) Assay
New
Luteinizing Hormone Assay
DRG LH-Serum ELISA Kit

Print article

Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.